Sumitomo PharmaSumitomo Pharma Co., Ltd.4506東証プライム医薬品FY ending Mar 2026, consolidated, IFRS

Sumitomo Pharma FY ending Mar 2026 results

About 75% of Sumitomo Pharma's sales come from North America, with Japan and Asia making up much of the rest.

Out of every ¥100 of sales, about ¥24 is left as operating profit.

Revenue changed +13.7% from the prior year, operating profit +272.6%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +13.7% · profit +272.6%, calculated from disclosed figures.

Operating leverage: 19.97× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +13.7%¥398.8B → ¥453.3B
Gross profit: +4.7%¥245.4B → ¥256.9B
Operating income: +272.6%¥28.8B → ¥107.3B
Net income attributable to owners: +352.2%¥23.6B → ¥106.9B
Operating cash flow: +334.6%¥16.5B → ¥71.7B
Free cash flow: +1756.0%¥3.47B → ¥64.4B

Results at a glance

Revenue for FY ending Mar 2026 was ¥453.3B, up +13.7% from ¥398.8B.
Profit grew much faster than sales: operating income rose from ¥28.8B to ¥107.3B (+272.6%), and net income attributable to owners from ¥23.6B to ¥106.9B (+352.2%).
Operating cash flow also climbed +334.6% to ¥71.7B, and free cash flow reached ¥64.4B.

What drove the change

Sales of Orgovyx and Gemtesa grew in North America, and the company booked a sales milestone payment for Orgovyx
Restructuring, including job cuts, and the reorganization of the regenerative and cell medicine business lowered SG&A and R&D costs
A gain from selling part of its stake in the Asia business was booked as other income

Things to watch

Sales rely heavily on Orgovyx and Gemtesa in North America, so new competitors or generics could cut revenue
Drugs in development may not reach approval or launch as planned
Drug pricing curbs in Japan, the US and China could hurt results

Annual Securities Report, 206th fiscal period (Apr 2025 - Mar 2026) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual Securities Report, 206th fiscal period (Apr 2025 - Mar 2026) / 事業等のリスク

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Sumitomo Pharma sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥43
SG&A: ¥36
Other costs: ¥3
Operating profit: ¥24
Net profit kept: ¥24

Annual margin trends

Gross margin56.7%

Operating margin23.7%

Net margin23.6%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

North America¥337.9B
75%
Op. margin 22.4%Industry: Pharmaceuticals
Japan¥92.4B
20%
Op. margin 13.4%Industry: Pharmaceuticals
Asia¥23B
5%
Op. margin 41.1%Industry: Pharmaceuticals

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (5)

EDINET (FSA Japan)
有価証券報告書－第206期(2025/04/01－2026/03/31)
ID S100YH3M2026-06-23Open
EDINET (FSA Japan)
有価証券報告書－第205期(2024/04/01－2025/03/31)
ID S100W63T2025-06-26Open
EDINET (FSA Japan)
有価証券報告書－第203期(2022/04/01－2023/03/31)
ID S100R4NL2023-06-27Open
EDINET (FSA Japan)
有価証券報告書－第202期(令和3年4月1日－令和4年3月31日)
ID S100O9PO2022-06-23Open
EDINET (FSA Japan)
有価証券報告書－第201期(令和2年4月1日－令和3年3月31日)
ID S100LN0R2021-06-24Open

Extracted from XBRL: 40 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image